GW's Epidiolex topped sales predictions, but investors bailed. What gives?

GW Pharma topped expectations with $86.1 million in Epidiolex sales in the third quarter. Still, investors punished the company, sending shares down by 15% on Wednesday. They might have overlooked some key data—or the drug simply failed to hit "whisper numbers" circulating the Street, market watchers said.